Consenso latinoamericano de hipertensión en pacientes con diabetes tipo 2 y síndrome metabólico

dc.creatorLópez Jaramillo, Patricio
dc.creatorSánchez, Ramiro
dc.creatorDíaz, Margarita
dc.creatorCobos, Leonardo
dc.creatorBrice, Alfonso
dc.creatorParra Carrillo, José Z.
dc.creatorLizcano, Fernando
dc.creatorLanas, Fernando
dc.creatorSinay, Isaac
dc.creatorSierra, Ivan
dc.creatorPeñaherrera, Ernesto
dc.creatorBenderky, Mario
dc.creatorSchmid, Helena
dc.creatorBotero, Rodrigo
dc.creatorUrina, Manuel
dc.creatorLara, Jofre
dc.creatorFoos, Milton
dc.creatorMárquez, Gustavo
dc.creatorHarrap, Stephen
dc.creatorRamírez, Agustín
dc.creatorZanchetti, Alberto
dc.date2013-06-28
dc.identifierhttps://revistas.unimilitar.edu.co/index.php/rmed/article/view/1164
dc.identifier10.18359/rmed.1164
dc.descriptionEl presente documento ha sido preparado por un grupo de expertos, miembros de las sociedades de cardiología, endocrinología, medicina interna, nefrología y diabetes de los países de América Latina, para que sirva de guía a los médicos que cuidan a pacientes con diabetes, hipertensión y enfermedades concomitantes o complicaciones de ambas condiciones. Aunque el concepto de síndrome metabólico actualmente es discutido, la alta prevalencia en América Latina del conjunto de alteraciones metabólicas que lo conforman sugiere que el síndrome metabólico es una entidad nosografías útil en el contexto de la medicina atinoamericana. Por lo tanto, en el presente documento se presta especial atención a este síndrome con el fin de alertar a los médicos de una particular población de alto riesgo, en la que por lo general se subestimada y no se trata en forma optima los factores de riego que constituyen el síndrome metabólico. Las presentes recomendaciones son el resultado de las presentaciones y los debates en los paneles de discusión durante una reunión de 2 días celebrada en Bucaramanga en octubre de 2012.Todos los participantes han aprobado las conclusiones finales. Los autores reconocen que la publicación y difusión de las guías no serán suficientes para alcanzar los cambios recomendados, tanto en las estrategias diagnósticas como terapéuticas, por lo que se ha programado intervenciones que permitan identificar las barreras del conocimiento, de las actitudes y de comportamiento, lo que permitirá tanto a los médicos como a los pacientes una adecuada adherencia a las recomendaciones de las guías.
dc.formatapplication/pdf
dc.languagespa
dc.publisherUniversidad Militar Nueva Granada
dc.relationhttps://revistas.unimilitar.edu.co/index.php/rmed/article/view/1164/896
dc.relation/*ref*/World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on managementof hypertension. J Hypertens. 2003; 21: 1983-1992.
dc.relation/*ref*/European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003;21: 1011-1053.
dc.relation/*ref*/Delamothe T. Wanted: guidelines that doctors will follow. BMJ.1993; 307(6898):218.
dc.relation/*ref*/McColl A, Smith H, White P, Field J. General practitioners’perceptions of the route to evidence based medicine: a questionnaire survey. BMJ. 1998; 316:361-365.
dc.relation/*ref*/Woolf SH. Practice guidelines, a new reality in medicine. II.Methods of developing guidelines. Arch Intern Med. 1992;152:946-952.
dc.relation/*ref*/Cabana MD, Rand CS, Powe NR, Wu AW, Wilson MH, Abboud PA, Rubin HR. Why don’t physicians follow clinical practice guidelines? A framework for improvement. JAMA. 1999;282(15):1458-1465.
dc.relation/*ref*/World Health Organization. Preventing chronic diseases: a vital investment: WHO global report. Geneva: World Health Organization; 2005. Page 1-13. [cited 2012 Sep 10]. Available from: http://www.who.int/chp/chronic_disease_report/en/
dc.relation/*ref*/Organización Panamericana de la Salud. Las Américas: una población creciente urbana que está envejeciendo. Washington: OPS; 2002. [cited 2012 Sep 10]. Available from: http://www.paho.org/Spanish/DBI/MDS/Press1_SEA_2002.htm
dc.relation/*ref*/Organización Panamericana de la Salud. Salud en las Américas 2007. Washington: OPS; 2007. [cited 2012 Sep 10]. Available from: http://www.paho.org/hia/home.html
dc.relation/*ref*/Sánchez RA, Ayala M, Baglivo H, Velázquez C, Burlando G, Kolmann O, et al, on behalf of the Latin American expert Group.Latin American guidelines on Hypertension. J Hypertens. 2009;27: 905-922.
dc.relation/*ref*/Ezzati M, Lopez AD, Rodgers A, Van der Hoorn S, Murray CJ.Comparative Risk Assessment Collaborating Group. Selected major risk factors and global and regional burden of disease.Lancet. 2002; 360: 1347-1360.
dc.relation/*ref*/Schargrodsky H, Hernández-Hernández R, Champagne BM,Silva H, Vinueza R, Silva-Ayçaguer LC, et al. for the CARMELA study. CARMELA: assessment of the CV risk in seven Latin American cities. Am J Med. 2008; 121: 58-65.
dc.relation/*ref*/Barreto S, Azeredo V, Oliveira J, Guerra H, Guati-Mosim P, Furtado M. Hypertension and clustering of cardiovascular risk factors in a community in southeast Brazil. The Bambuí Health and Ageing Study. Arq Bras Cardiol. 2001; 77:576-581.
dc.relation/*ref*/Jiménez J, Palacios M, Cañete F, Barriocanal L, Medina U, Figueredo R, et al. Prevalence of diabetes mellitus and associated cardiovascular risk factors in an adult urban population in Paraguay. Diabetic Medicine. 1998; 15:334-338.
dc.relation/*ref*/Fasce E, Campos I, Ibañez P, Flores M, Zarate H, Román O, Fasce F. Trends in prevalence, awareness, treatment and control of hypertension in urban communities in Chile. J Hypertens. 2007; 25: 1807-1811.
dc.relation/*ref*/Guerrero-Romero F, Rodríguez M. Prevalencia de hipertensión arterial y factores asociados en la población rural marginada.Salud Pública México. 1998; 40:339-346.
dc.relation/*ref*/Teo K, Chow CK, Vaz M, Ranjarajan S, Yusuf S; PURE Investigators-Writing Group. The Prospective Urban Rural Epidemiology (PURE) study: examining the impact of societal influences on chronic non-communicable diseases in low-, middle-, and high-income countries. Am Heart J. 2009; 158:1-7.
dc.relation/*ref*/Sempértegui F, Estrella B, Tucker KL, Hamer DH, Narvaez X, Sempértegui M, et al. Metabolic syndrome in the elderly living in marginal peri-urban communities in Quito, Ecuador. Public Health Nutr. 2011; 14: 758-767.
dc.relation/*ref*/Alvarez C, Salazar R, Galindez J, Rangel F, Castañeda ML, Lopardo G, et al. Metabolic syndrome in HIV-infected patients receiving antiretroviral therapy in Latin America. Braz J Infect Dis. 2010; 14: 256-263.
dc.relation/*ref*/Bermúdez V, Marcano RP, Cano C, Arráiz N, Amell A, Cabrera M, et al. The Maracaibo city metabolic syndrome prevalence study: design and scope. Am J Ther. 2010; 17: 288-294.
dc.relation/*ref*/Escobedo J, Schargrodsky H, Champagne B, Silva H, Boissonnet CP, Vinueza R, et al. Prevalence of the metabolic syndrome in Latin America and its association with sub-clinical carotid atherosclerosis: the CARMELA cross sectional study. Cardiovasc Diabetol. 2009; 26: 8-52.
dc.relation/*ref*/Caceres M, Teran CG, Rodriguez S, Medina M. Prevalence of insulin resistance and its association with metabolic syndrome criteria among Bolivian children and adolescents with obesity. BMC Pediatr. 2008; 8:31.
dc.relation/*ref*/Royer M, Castelo-Branco C, Blümel JE, Chedraui PA, Danckers L, Bencosme A, et al. Collaborative Group for Research of the Climacteric in Latin America. The USA National Cholesterol Education Programme Adult Treatment Panel III (NCEP ATP III): prevalence of the metabolic syndrome in postmenopausal Latin American women. Climacteric. 2007; 10: 164-170.
dc.relation/*ref*/Bustos P, da Silva AA, Amigo H, Bettiol H, Barbieri MA. Metabolicsyndrome in young adults from two socio-economic LatinAmerican settings. Nutr Metab Cardiovasc Dis. 2007; 17: 581-589.
dc.relation/*ref*/Rueda-Clausen C, Silva F, López-Jaramillo P. Epidemic of obesity and overweigh in Latin America and the Caribbean.Int J Cardiol. 2008; 123; 111-112.
dc.relation/*ref*/Garcia RG, Pérez M, Maas R, Schwedhelm E, Böger RH, López-Jaramillo P. Plasma Concentrations of Asymmetric Dimethylarginine (ADMA) in Metabolic Syndrome. Int J Cardiol.2007; 122: 176-178.
dc.relation/*ref*/López-Jaramillo P, Rueda-Clausen C, Silva FA. The utility of different definitions of metabolic syndrome in Andean population. Int J Cardiol. 2007; 116: 421-422.
dc.relation/*ref*/Garcia RG, Cifuentes AE, Caballero RS, Sánchez L, López- Jaramillo P. A proposal for an appropriate central obesity diagnosis in Latin American population. Int J Cardiol. 2005; 110: 263-264.
dc.relation/*ref*/Pérez M, Casas JP, Cubillos LA, Serrano NC, Silva FA, Morillo CA, et al. Using waist circumference as screening tool to identify Colombian subjects at cardiovascular risk. Eur J Cardiovasc Preven and Rehab. 2003; 10: 328-335.
dc.relation/*ref*/Pinzón JB, Serrano NC, Díaz LA, Mantilla G, Velasco HM,Martínez LX, et al. Impacto de las nuevas definiciones en la prevalencia de síndrome metabólico en una población de Bucaramanga, Colombia. Biomédica. 2007; 27: 172-179.
dc.relation/*ref*/Piegas LS, Avenzum A, Pereira JC, Neto JM, Hoepfner C, Farran JA, et al. Risk factors for myocardial infarction in Brazil.Am Heart J. 2003; 146: 331-338.
dc.relation/*ref*/Messiah SE, Carrillo-Iregui A, Garibay-Nieto N, López-Mitnik G, Cossio S, Arheart KL. Prevalence of metabolic syndrome in US-born Latin and Caribbean youth. J Immigr Minor Health.2009;11:366-371.
dc.relation/*ref*/Velásquez-Meléndez G, Kac G, Valente JG, Tavares R, SilvaCQ, Garcia ES. Evaluation of waist circumference to predict general obesity and arterial hypertension in women in Greater Metropolitan Belo Horizonte, Brazil. Cad Saude Publica. 2002; 18: 765-771.
dc.relation/*ref*/Berber A, Gómez Santos R, Fanghanel G, Sanchez- Reyes L.Anthropometric indexes in the prediction of type 2 diabetesmellitus, hypertension and dyslipidaemia in a Mexican population.Int J Obes Relat Metab Disord. 2001; 25: 1794-1799.
dc.relation/*ref*/Kabagambe EK, Baylin A, Campos H. Non-fatal acute myocardial infarction in Costa Rica: Modifiable risk factors, population attributable risk, and adherence to dietary guidelines. Circulation.2007; 115: 1075-1081.
dc.relation/*ref*/Manzur F, Alvear C, Alayón A. Caracterización fenotípica y metabólica del síndrome metabólico en Cartagena de Indias.Rev Colomb Cardiol. 2008; 15: 97-101.
dc.relation/*ref*/Sánchez F, Jaramillo N, Vanegas A, Echeverría JG, León AC,Echeverría E, et al. Prevalencia y comportamiento de los factores de riesgo del síndrome metabólico según los diferentes intervalos de edad, en una población femenina del área de influencia de la Clínica Las Américas, en Medellín -Colombia Rev Colomb Cardiol. 2008; 15: 102-110.
dc.relation/*ref*/Villegas A, Botero J, Arango I, Arias S, Toro M. Prevalencia del síndrome metabólico en El Retiro, Antioquia, Colombia.Iatreia. 2003; 16: 291-297.
dc.relation/*ref*/Merchán A. Síndrome metabólico y riesgo de enfermedad cardiovascular. Acta Med Colomb. 2005; 30: 150-154.
dc.relation/*ref*/Lombo B, Villalobos C, Tique C, Satizábal C, Franco C. Prevalencia del síndrome metabólico entre los pacientes que asisten al servicio de la clínica de hipertensión de la Fundación Santa Fe de Bogotá. Rev Colomb Cardiol. 2006; 12: 472-478.
dc.relation/*ref*/Aschner P. Síndrome metabólico en una población rural y una población urbana de la región andina colombiana. Rev Med.2007; 15: 154-162.
dc.relation/*ref*/Márquez-Sandoval F, Macedo-Ojeda G, Viramontes-Hörner D, FernándezBallart JD, Salas Salvadó J, Vizmanos B. The prevalence of metabolic syndrome in Latin America: a systematic review. Public Health Nutr. 2011; 14: 1702-1713
dc.relation/*ref*/Guerrero-Romero F, Rodríguez M, Sandoval F, Alvarado R. Prevalence of hypertension in indigenous inhabitants of traditionalcommunities from north of Mexico. J Hum Hypertens.000; 14:555-559.
dc.relation/*ref*/Sichieri R. Dietary patterns and their association with obesity in the Brazilian city of Rio de Janeiro. Obes Res. 2002; 10:42-48.
dc.relation/*ref*/Arroyo P, Loria A, Fernandez V, Flegal KM, Kuri P. Prevalence of pre-obesity in urban adult Mexicans in comparison with other large surveys. Obes Res. 2000; 8:179-185.
dc.relation/*ref*/Sereday M, Gonzalez C, Giorgini P, De Loredo L, Braguinsky J, Cobeñas C, et al. Prevalence of diabetes and obesity in the central area of Argentina. Diabetes Metab. 2003; 29: 5S28-5S43.
dc.relation/*ref*/Wilks R, Rotimit C, Bennet F, McFarlane-Anderson N, Kaufmant JS, Anderson SG, et al. Diabetes in the Caribbean: results of a population survey from Spanish Town, Jamaica. Diab Med.1999; 16:875-883.
dc.relation/*ref*/Piskorz, D. Factores de riesgo en la ciudad de Rosario. Resultados del Estudio FAROS. Revista de la Federación Argentina de Cardiología. 1999; 64:245-251.
dc.relation/*ref*/Avila Curiel A, Shamah- Levy T, Chávez -Villasana A, Galindo Gómez C. Encuesta Urbana de Alimentación y Nutrición en la Zona Metropolitana de la ciudad de México 2002. México DF: Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Instituto Nacional de Salud Pública, 2003.
dc.relation/*ref*/De Onis M, Blössnner M. Prevalence and trends of overweight among preschool children in developing countries. Am J Clin Nutr. 2000; 72:1032-1039.
dc.relation/*ref*/Martorell R, Kettel Khan L, Hughes M, Grummer-Strawn. Obesity in Latin American women and children. J Nut. 1998; 128:1464-1473.
dc.relation/*ref*/Monteiro CA. Epidemiologia da Obesidade.In: Halpern A, Matos AFG, Suplicy H, Mancini MC & Zanella MT (eds). Obesidade.Editorial Lemos: São Paulo, 1998; pp.15-30.
dc.relation/*ref*/Pisabarro R, Gutiérrez M, Bermúdez C, Préndez D, Recalde A, Chaftare Y, Manfredi A. Segunda encuesta nacional de sobrepeso y obesidad (ENSO 2) en adultos. Rev Med Urug.2009; 25: 14-26.
dc.relation/*ref*/Orduñez P, Espinosa A, Cooper R, Kaufman J, Nieto F. Hypertension in Cuba: evidence of narrow black-white difference. J Hum Hypertens. 1998; 12:111-116.
dc.relation/*ref*/Magalhães N, Pozzan R, Brandão AA, Cerqueira R, Rousoulieres A, Szwarcwald C, Brandão A. Early blood pressure level as a mark of familial aggregation of metabolic cardiovascular risk factors.The Rio de Janeiro Study. J Hypertens. 1998; 6:1885-1889.
dc.relation/*ref*/Díaz ME. Hypertension and obesity. J Hum Hypertens. 2002, 16 (Suppl 1):S18-S22.
dc.relation/*ref*/Filozof C, Gonzalez C, Sereday M, Mazza C, Braguinsky J.Obesity prevalence and trends in Latin American countries.Obes Rev. 2001; 2: 99–106.
dc.relation/*ref*/Samper-Ternent R, Michaels-Obregon A, Wong R. Coexistence of obesity and anemia in older Mexican adults. Ageing Int.2011; 37:104-117.
dc.relation/*ref*/Monteiro CA, Moura EC, Conde WL, Popkin BM. Socioeconomic status and obesity in adult populations of developing countries:a review. Bull World Health Organ. 2004; 82: 940-946.
dc.relation/*ref*/Monteiro CA, Conde WL, Lu B, Popkin BM. Obesity and inequities in health in the developing world. Int J Obes Relat Metab Disord. 2004; 28: 1181–1186.
dc.relation/*ref*/Williams K, Stern MP, Gonzalez-Villalpando C. Secular trends in obesity in Mexico City and in San Antonio. Nutr Rev. 2004;62:S158–S162.
dc.relation/*ref*/Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI,Donato KA, et al. Harmonizing the metabolic syndrome. A Joint Interim Statement of the International Diabetes FederationTask Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation.2009; 120:1640-1645.
dc.relation/*ref*/Reaven GM. Insulin resistance/compensatory hyperinsulinemia, essential hypertension, and cardiovascular disease. J Clin Endocrinol Metab. 2003; 88: 2399-2403.
dc.relation/*ref*/Aschner P, Buendía R, Brajkovich I, Gonzalez A, Figueredo R, Juarez XE, et al. Determination of the cut-off point for waist circumference that establishes the presence of abdominal obesity in Latin American men and women. Diabetes Res Clin Pract.2011; 93: 243-247.
dc.relation/*ref*/American Diabetes Association. Executive summary: standards of medical care in diabetes. 2010. Diabetes Care. 2010;33 (Suppl 1): S4–S10.
dc.relation/*ref*/Schriger DL, Lorber B. Lowering the cut point for impaired fasting glucose: where is the evidence? Where is the logic? Diabetes Care. 2004;27:592-601.
dc.relation/*ref*/Rutter MK, Nesto RW. Blood pressure, lipids and glucose in type 2 diabetes: how low should we go? Re-discovering personalized care. Eur Heart J. 2011; 32: 2247-2255.
dc.relation/*ref*/Jonsson B. Revealing the cost of Type II diabetes in Europe.Diabetologia. 2002; 45:S5-S12.
dc.relation/*ref*/Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The Seventh Report of the Joint NationalCommittee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 report. JAMA. 2003;289:2560-2572.
dc.relation/*ref*/Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens.2007; 25:1105-1187.
dc.relation/*ref*/Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caufield MJ, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens. 2009;27:2121-2158.
dc.relation/*ref*/Staessen JA, Asmar R, De Buyzere M, Imai Y, Parati G, Shimada K, et al. Participants of the 2001 Consensus Conference on Ambulatory Blood Pressure Monitoring. Task Force II. Blood pressure measurement and cardiovascular outcome. Blood Press Monit. 2001; 6: 355-370.
dc.relation/*ref*/O’Brien E, Asmar R, Beilin L, Imai Y, Mallion JM, Mancia G,et al. European Society of Hypertension Working Group on Blood Pressure Monitoring. European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement. J Hypertens. 2003; 21: 821-848.
dc.relation/*ref*/Bonow RO, Mitch WE, Nesto RW, O’Gara PT, Becker RC, ClarkLT, et al. Prevention conference VI. Diabetes and Cardiovascular disease. Writing Group V: Management of Cardiovascular- Renal Complications. Circulation. 2002;105:159-164.
dc.relation/*ref*/Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis. 2000;36:646-661.
dc.relation/*ref*/DeFronzo RA. Diabetic nephropathy: etiologic and therapeutic considerations. Diabetes Rev. 1995; 3:510-564.
dc.relation/*ref*/Malmberg K, Norhammar A, Wedel H, Ryden L. Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acutemyocardial infarction: long term results from the Diabetes and Insulin-glucose Infusion in Acute Myocardial Infarction [DIGAMIstudy] Circulation. 1999; 99:2626-2632.
dc.relation/*ref*/Colwell JA.Aspirin Therapy in diabetes [Technical Review].Diabetes Care. 1997; 20:1767-1771.
dc.relation/*ref*/McDonagh TA, Morrison CE, Lawrence A, Ford I, Tunstall-Pedoe H, McMurray JJ, Dargie HJ. Symptomatic and asymptomatic left ventricular systolic dysfunction in an urban population. Lancet. 1997; 350:829-833.
dc.relation/*ref*/Iribarren C, Karter AJ, Go AS, Ferrara A, Liu JY, Sidney S, Selby JV. Glycaemic control and HF among adult patients with diabetes. Circulation. 2001;103:2668-2673.
dc.relation/*ref*/Bell DS. Heart Failure: the frequent, forgotten and often fatal complication of diabetes. Diabetes Care. 2003; 26:2433-2441.
dc.relation/*ref*/Marantz PR, Tobin JN, Wassertheil-Smoller S, Steingart RM, Wexler JP, Budner N, et al. The relationship between left ventricular function and congestive HF diagnosed by clinical criteria. Circulation. 1988;77: 607-612.
dc.relation/*ref*/Kasrapanayiotides T, Piechowski-Jozwiak B, Van Melle G, Bogousslavsky J, Devuyst G. Stroke Patterns, etiology and prognosis in patients with diabetes mellitus. Neurology. 2004;62:1558-1562.
dc.relation/*ref*/Megherbi SE, Milan C, Minier D, Couvreur G. Osseby GV, Tilling K, et al. Association between diabetes and stroke subtype on survival and functional outcome 3 months after stroke: data from the European BIOMED Stroke Project. Stroke. 2003; 34:688-694.
dc.relation/*ref*/Stevens RJ, Coleman RL, Adler AI, Stratton IM, Matthews DR,Holman RR. Risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes: UKPDS 66. DiabetesCare. 2004;27:201-207.
dc.relation/*ref*/Shepard R, Balady G. Exercise as cardiovascular therapy. Circulation. 1999; 99: 963-972.
dc.relation/*ref*/American Diabetes Association. Position Statement. Diabetes mellitus and exercise. Diabetes Care. 2000; 23 [suppl 1]: S50-S54.
dc.relation/*ref*/Walker KZ, Piers LS, Putt RS Jones JA, O´Dea K. Effects ofregular walking on cardiovascular risk factors and body composition in normoglycaemic woman and woman with type 2 diabetes. Diabetes Care. 1999; 22: 555-561.
dc.relation/*ref*/Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment [HOT] randomised trial. Lancet. 1998; 351:1755–1762.
dc.relation/*ref*/UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-713.
dc.relation/*ref*/Curb JD, Pressel SL, Cutler JA, Savage PJ, Applegate WB,Black H, et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in theElderly Program Cooperative Research Group. JAMA. 1996; 276:1886–1892.
dc.relation/*ref*/Tuomilehto J, Rastenyte D, Birkenhäger WH, Thijs L, Antikainen R, Bulpitt CJ, et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N Engl J Med. 1999;340:677–684.
dc.relation/*ref*/Estacio RO, Jeffers BW, Gifford N, Schrier RW. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care.2000;23 (Suppl 2): S54-S64.
dc.relation/*ref*/Heart Outcomes Prevention Evaluation (HOPE) Study investigators.Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICROHOPE substudy. Lancet. 2000; 355:253–259.
dc.relation/*ref*/Cooper-DeHoff RM, Gong Y, Handberg EM, Bavry AA, Denardo SJ, Bakris GL, Pepine CJ. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA. 2010:304:61-68.
dc.relation/*ref*/Zanchetti A, Grassi G, Mancia G. When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal. J Hypertens.2009; 27:923–934
dc.relation/*ref*/ACCORD Study group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010; 362:1575-1585.
dc.relation/*ref*/Bangalore S, Kumar S, Lobach I, Messerli FH. Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observation from traditional and Bayesian randomeffects meta-analysis of randomized trials. Circulation. 2011; 23:2799-2810.
dc.relation/*ref*/Reboldi G, Gentile G, Angeli F, Ambrosio G, Mancia G, Verdecchia P. Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: a meta-analysis in 73,913 patients. J Hypertens. 2011; 29:1253 -1169.
dc.relation/*ref*/Patel A, ADVANCE Collaborative Group, MacMahon S, Chalmers J, Neal B, Woodward M, et al. Effects of a fixed combination of perindropil and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial). Lancet. 2007; 370: 829-840.
dc.relation/*ref*/Lewis JB. Blood pressure control in chronic kidney disease: is less really more? J Am Soc Nephrol. 2010; 21: 1086-1092.
dc.relation/*ref*/Turnbull F, Neal B, Ninomiya T, Algert C, Arima H, et al., Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med. 2005; 165:1410–1419.
dc.relation/*ref*/Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, et al., ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547-1559.
dc.relation/*ref*/Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008; 359:2417-2428.
dc.relation/*ref*/U.S. Food and Drug Administration. FDA Drug Safety Communication: New Warning and Contraindication for blood pressure medicines containing aliskiren (Tekturna). Rockville, USA: U.S. Food and Drug Administration; 2012. [cited 2012 Sep 10]. Available from: http://www.fda.gov/drugs/drugsafety/ucm300889.htm
dc.relation/*ref*/Stears AJ, Woods SH, Watts M, Burton TJ, Graggaber J, MirFA, Brown MJ. A double-blind, placebo-controlled, crossovertrial comparing the effects of amiloride and hydrochlorothiazideon glucose tolerance in patients with essential hypertension.Hypertension. 2012; 59: 934-942.
dc.relation/*ref*/Central Intelligence Agency-CIA. The World Factbook. Washington, USA: Central Intelligence Agency-CIA; 2012. [cited 2012 Aug 10]. Available from: https://www.cia.gov/library/publications/the-world-factbook/wfbExt/region_soa.html
dc.relation/*ref*/Sanchez–Johnsen LA, Fitzgibbon ML, Martinovich Z, Stolley MR, Dyer AR, Van Horn L. Ethnic differences in correlates of obesity between Latin–American and black women. Obes Res.2004; 12:652-660.
dc.relation/*ref*/Barcelo A, Gregg EW, Partor-Valero M, Robles SC. Waist circumference, BMI and the prevalence of self-reported diabetes among the elderly of the United States and six cities of Latin American and the Caribbean. Diabetes Res Clin Pract. 2007;78:418-427.
dc.relation/*ref*/Anselmi M, Avanzini F, Moreira JM, Montalvo G, Armani D, Prandi R, et al. Treatment and control of arterial hypertension in a rural community in Ecuador. Lancet. 2003; 36: 1186-1187.
dc.relation/*ref*/Flack JM, Sica DA, Bakris G, Brown AL, Ferdinand KC, Grimm Jr RH, et al. Management of High Blood Pressure in Blacks. An Update of the International Society on Hypertension in Blacks Consensus Statement on behalf of the International Society on Hypertension in Blacks. Hypertension. 2010, 56: 780-800.
dc.relation/*ref*/Burke GL, Savage PJ, Manolio TA, Sprafka JM, Wagenknecht LE, Sidney S, et al. Correlates of obesity in young black and white women: the CARDIA Study. Am J Public Health. 1992;82: 1621–1625.
dc.relation/*ref*/Sharp TA, Bell ML, Grunwald GK, Schmitz KH, Sidney S, Lewis CE, et al. Differences in resting metabolic rate between white and African-American young adults. Obes Res. 2002; 10: 726–732.
dc.relation/*ref*/McVlellan W, Tuttle E, Issa A. Racial Differences in the incidence of hypertensive end-stage renal disease. Am J Kidney Dis.1998; 12: 285-290
dc.relation/*ref*/Lopes AA, Port FK. The low birth weight hypothesis as a plausible explanation for the black/white differences in hypertension,non-insulin-dependent diabetes, and end-stage renal disease.Am J Kidney Dis. 1995; 25: 350.
dc.relation/*ref*/Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, et al. Heart Diseases and stroke statistics: 2011 update a report from de American Heart Association. Circulation. 2011;123:18-1209
dc.relation/*ref*/Sareli P, Radevski IV, Valtchanova ZP, Libhaber E, Candy GP,Den Hond E, et al. Efficacy of different drug classes used to initiate antihypertensive treatment in black subjects: results of a randomized trial in Johannesburg, South Africa. Arch Intern Med. 2001;161(7):965-971.
dc.relation/*ref*/Wright JT Jr, Dunn JK, Cutler JA, Davis BR, Cushman WC, Ford CE, et al. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril.JAMA. 2005;293(13):1595-608.
dc.relation/*ref*/Brown NJ, Ray WA, Snowden M, Griffin MR. Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema. Clin Pharmacol Ther.1996;60(1):8-13.
dc.relation/*ref*/Medina-Lezama J, Zea–Diaz H, Morey–Vargas OL, Bolaños–Salazar JF, Postigo–Macdowall M, Paredes-Diaz S, et al.Prevalence and patterns of hypertension in Peruvian Andean Hispanics: the PREVENCION study. J Am Soc Hypertens.2007; 1:216-225.
dc.relation/*ref*/Agusti R. Epidemiologia de la hipertensión arterial en el Perú.Acta Med Per. 2006; 23(2): 69-75.
dc.relation/*ref*/Organización Panamericana de la Salud. Base de Datos de Indicadores Básicos en Salud de la OPS. Washington: OPS;2007. [cited 2012 Sep 10]. Available from: http://www.paho.org/spanish/dd/ais/cp_152.htm
dc.relation/*ref*/Vasan RS, Beiser A, Seshadri S, Larson MG, Kannel WB,D’Agostino RB, Levy D. Residual lifetime risk for developing hypertension in middle-aged women and men: the Framingham Heart Study. JAMA. 2002;287:1003-1010
dc.relation/*ref*/Benetos A, Safar M, Rudnichi A, Smulyan H, Richard JL,Ducimetiére P, Guize J. Pulse pressure: a predictor of longterm cardiovascular mortality in a French male population. Hypertension. 1997; 30:1410-1415.
dc.relation/*ref*/Silagy CA, McNeil JJ, Farish S, Mc Grath BP, Comparation of repeated measurement of ambulatory and clinic blood pressure readings in isolated systolic hypertension. Clin Exp Hypertension.1995; 15: 895-909.
dc.relation/*ref*/Wiinberg N, Hoegholm A, Christensen HR, Bang LE, Mikkelsen KL, Nielsen PE, et al. 24-h-ambulatory blood pressure in 352 normal Danish subjects, related to age and gender. Am J Hypertens. 1995; 8: 978-986.
dc.relation/*ref*/Kario K, Pickering TG, Matsuo T, Hoshide S, Schwartz JE, Shimada K. Stroke prognosis and abnormal nocturnal blood pressure falls in older hypertensive. Hypertension. 2001; 38:852-857.
dc.relation/*ref*/Kario K, Pickering TG, Umeda Y, Hoshide S, Hoshide Y, Morinari M, et al. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. Circulation. 2003; 107:1401-1406.
dc.relation/*ref*/Verdecchia P, Angeli F, Mazzotta G, Garofoli M, Ramundo E, Gentile G, et al. Day-night dip and early-morning surge in blood pressure in hypertension: prognostic implications.Hypertension. 2012; 60: 34-42.
dc.relation/*ref*/Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, et al. HYVET Study Group, Treatment of hypertension in patients 80 years of age or older. N Eng J Med. 2008;358: 1887-1898.
dc.relation/*ref*/SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265(24):3255-3264.
dc.relation/*ref*/Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenha¨ger WH, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet. 1997; 350: 757–764.
dc.relation/*ref*/Liu L, Wang JG, Gong L, Liu G, Staessen JA. comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension, Systolic Hypertension in China (SYST-CHINA) Collaborative Group. J Hypertension.1998;16:1823-1829.
dc.relation/*ref*/Lopez-Jaramillo P, Lahera V, Lopez-Lopez J. Epidemic of cardiometabolic diseases: A Latin American point of view.Ther Adv Cardiovasc Dis. 2011; 5: 119-131.
dc.relation/*ref*/López-Jaramillo P, Silva SY, Rodríguez Salamanca N, Duran A, Mosquera W, Castillo V. Are Nutrition-Induced EpigeneticChanges the Link Between Socioeconomic Pathology and Cardiovascular Diseases? Am J Therap. 2008; 15:362-372.
dc.relation/*ref*/López-Jaramillo P. Cardio-metabolic disease in Latin America: the role of fetal programming in response to maternal malnutrition.Rev Esp Cardiol. 2009; 62: 670-676.
dc.relation/*ref*/Fernandes MT, Sesso R, Martins PA, Sawaya AL. Increased blood pressure in adolescents of socioeconomic status with short stature. Pediatr Nephrol. 2003; 18: 435-439.
dc.relation/*ref*/Florêncio TT, Ferreira HS, Cavalcante JC, Sawaya AL. Short stature, obesity and arterial hypertension in a very low income population in North-eastern Brazil. Nutr Metab Cardiovasc Dis.2004; 14: 26-33.
dc.relation/*ref*/Ferreira HS, Moura FA, Cabral CR Jr, Florêncio TM, Vieira RC, de Assunção ML. Short stature of mothers from an area endemic for under-nutrition is associated with obesity, hypertension and stunted children: A population-based study in the semi-arid region of Alagoas, Northeast Brazil. Br J Nutr. 2009; 101: 1239-1245.
dc.relation/*ref*/López-Jaramillo P, Herrera E, Garcia RG, Camacho PA, Castillo VR. Inter-relationships between body mass index, C-reactive protein and blood pressure in a Hispanic pediatric population.Am J Hypertens. 2008; 21: 527-532.
dc.relation/*ref*/Franco MC, Casarini DE, Carneiro-Ramos MS, Sawaya AL,Barreto-Chaves ML, Sesso R. Circulating renin-angiotensin system and catecholamines in childhood: is there a role for birth weight? Clin Sci (Lond). 2008: 114, 375-380.
dc.relation/*ref*/Febba A, Sesso R, Barreto GP, Liboni CS, Franco MC, Casarini DE. Stunting growth: Association of the blood pressure levels and ACE activity in early childhood. Pediatr Nephrol. 2009;24: 379-386.143. González-Barranco J, Ríos-Torres JM, Castillo-Martínez L, López-Alvarenga JC, Aguilar-Salinas CA, Bouchard C, et al. Effect of malnutrition during the first year of life on adult plasma insulin and glucose tolerance. Metabolism. 2003; 52: 1005-1011.
dc.relation/*ref*/Lopez-Jaramillo P. Defining the research priorities to fight the burden of cardiovascular diseases in Latin America. J Hypertens. 2008; 26: 1886-1889.
dc.rightsDerechos de autor 2015 Revista Med
dc.sourceRevista Med; Vol. 21 No. 1 (2013): january - june; 115-137
dc.sourceRevista Med; Vol. 21 Núm. 1 (2013): enero - junio; 115-137
dc.source1909-7700
dc.source0121-5256
dc.subjecthipertensión arterial
dc.subjectdiabetes
dc.subjectsíndrome metabólico
dc.subjectConsenso Latinoamericano
dc.titleConsenso latinoamericano de hipertensión en pacientes con diabetes tipo 2 y síndrome metabólico
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion


Este ítem pertenece a la siguiente institución